New protocols, remote patient monitoring, and improved standards of care among ways industry can take next steps in CAR T-cell research.
Jaydev Thakkar, MBA
Advertisement
Jaydev Thakkar, MBA, MCA, is Chief Operating Officer of Biofourmis
Articles by Jaydev Thakkar, MBA
Advertisement
Latest Updated Articles
How Today’s Digitally Driven Research Could Drive CAR T-cell Therapy Protocols of the FuturePublished: September 25th 2023 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: AstraZeneca Expands Immunotherapy Reach as Thermo Fisher’s $8.8B Deal Signals New Phase for Digital Trials
2
Engineered Bispecific Antibodies: Regulatory, Ethical, and Best Practice Guidelines
3
MATTERHORN Trial Findings Signal Paradigm Shift in Early Gastric Cancer Care
4
ACT Brief: AI, Equity, and Innovation Drive Clinical Research Forward
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
